Vericiguat: clinical trials recruiting now

FDA drug label

FDA-approved

Yes. Vericiguat appears in the FDA drug-label database. Marketed as VERQUVO.

Drug class

Soluble Guanylate Cyclase Stimulator (FDA established pharmacologic class)

Mechanism of action

Guanylate Cyclase Stimulators (as stated on the FDA label)

Boxed warning

The FDA label for Vericiguat carries a boxed warning (the FDA's most serious warning). See the full label for details.

FDA-approved use

VERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ] . VERQUVO is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%. ( 1 )

FDA label via openFDA